Clinical features and prognosis of diffuse large B-cell lymphoma with hepatitis B virus infection
10.16571/j.cnki.1008-8199.2019.03.006
- VernacularTitle: 乙型肝炎病毒感染的弥漫大B细胞淋巴瘤患者临床特点及预后分析
- Author:
Yuan-yuan SUN
1
;
Ming-zhi ZHANG
1
Author Information
1. Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450001,Henan, China
- Publication Type:Journal Article
- Keywords:
hepatitis B virus;
diffuse large B cell lymphoma;
lactate dehydrogenase;
clinical features;
survival and prognosis
- From:
Journal of Medical Postgraduates
2019;32(3):253-257
- CountryChina
- Language:Chinese
-
Abstract:
Objective The association of hepatitis B virus (HBV) infection with the clinical features and prognosis of diffuse large B-cell lymphoma (DLBCL) remains unclear. This study aimed to investigate the relationship between HBV infection and the clinical characteristics and prognosis of DLBCL. Methods This retrospective included 199 cases of DLBCL initially treated in our Department of Oncology from January 2012 to December 2017, which fell into an HBV group (n = 92) and a non-HBV group (n = 107). We recorded the clinical features, liver function before and during the treatment, progression-free survival and overall survival of the patients. Based on the level of lactate dehydrogenase (LDH) and the presence of HBV infection, we again divided the patients into four groups: normal (non-HBV infection and normal LDH, n = 67), high LDH (without HBV infection, n = 40), HBV (HBV infection with normal LDH, n = 59), and HBV+high LDH (with both HBV infection and high LDH, n = 33), and compared the results of treatment among different groups. Results The incidence rate of liver damage was significantly higher in the HBV than in the non-HBV group before chemotherapy (P < 0.05) but showed no statistically significant difference between the two groups during chemotherapy (P > 0.05). The rate of therapeutic effectiveness was remarkably lower in the HBV+high LDH than in the normal, high LDH and HBV groups (30.3% vs 82.1%, 87.5% and 88.1%, P < 0.01). The progression-free survival was markedly longer in the non-HBV than in the HBV group ([63.9 ± 2.4] vs [45.7 ± 2.9] mo, P = 0.004). Conclusion HBV infection is involved in the development and progression of DLBCL, and may act synergetically with high LDH and exerts a negative effect on the therapeutic efficacy.
